FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma

Show other versions (1)

Bibliographic Details
Main Authors:	Couillard, S, Shrimanker, R, Chaudhuri, R, Mansur, A, McGarvey, L, Heaney, L, Fowler, S, Bradding, P, Pavord, I, Hinks, T
Format:	Journal article
Language:	English
Published:	American Thoracic Society 2021

Similar Items

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
by: Couillard, S, et al.
Published: (2021)

Mechanisms of FeNO non-suppression in severe asthma: analysis of sputum type 2 cytokines and chemokines
by: Couillard, S, et al.
Published: (2020)

Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing
by: Couillard, S, et al.
Published: (2022)

Airway remodelling rather than cellular infiltration characterises both type2 cytokine biomarker-high and -low severe asthma
by: Khalfaoui, L, et al.
Published: (2022)

Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma
by: Heaney, LG, et al.
Published: (2018)

Sub-stratification of type-2 high airway disease for therapeutic decision-making: a ‘bomb' (blood eosinophils) meets ‘magnet' (FeNO) framework
by: Couillard, S, et al.
Published: (2022)

Exacerbations of severe asthma in patients treated with mepolizumab
by: Shrimanker, R, et al.
Published: (2018)

Prognostic value of using FeNO to guide step-down treatment decisions in asthma
by: Wang, K, et al.
Published: (2018)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
by: Shrimanker, R, et al.
Published: (2017)

Feno and blood eosinophils as biomarkers in predicting asthma exacerbations
by: Rastogi, S, et al.
Published: (2017)

The effect of oral corticosteroids on circulating type-2 cytokine producing cells in patients with severe eosinophilic asthma
by: Hynes, G, et al.
Published: (2018)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
by: Shrimanker, R, et al.
Published: (2017)

Emerging biologics in severe asthma
by: Pavord, I, et al.
Published: (2016)

Qualitative study on perceptions of use of Fractional Exhaled Nitric Oxide (FeNO) in asthma reviews
by: Santillo, M, et al.
Published: (2022)

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial
by: Hanratty, CE, et al.
Published: (2018)

Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.
by: Shrimanker, R, et al.
Published: (2017)

How I do it: workup of severe asthma
by: Couillard, S, et al.
Published: (2021)

Non-eosinophilic corticosteroid unresponsive asthma.
by: Pavord, I, et al.
Published: (1999)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
by: Howell, I, et al.
Published: (2024)

Reply to: inhaled corticosteroids and adult asthma
by: Beasley, R, et al.
Published: (2019)

Asthma progression and mortality: The role of inhaled corticosteroids
by: O'Byrne, P, et al.
Published: (2019)

Biomarkers predicting response to corticosteroid therapy in asthma.
by: Brightling, C, et al.
Published: (2005)

Prognostic value of FeNO-guided assessment to identify steroid-responsive respiratory symptoms
by: Wang, K, et al.
Published: (2018)

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.
by: Berry, M, et al.
Published: (2007)

Fractional exhaled nitric oxide non-suppression in asthma
by: Couillard Castonguay, S
Published: (2021)

Management and mechanisms of severe eosinophilic asthma
by: Shrimanker, R
Published: (2020)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
by: Moran, A, et al.
Published: (2020)

Oral corticosteroid-dependent asthma: current knowledge and future needs
by: Pavord, I
Published: (2019)

Current evidence and future research needs for FeNO measurement in respiratory diseases
by: Bjermer, L, et al.
Published: (2014)

Current evidence and future research needs for FeNO measurement in respiratory diseases.
by: Bjermer, L, et al.
Published: (2014)

Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis
by: Oliver, ME, et al.
Published: (2021)

Does a composite score combining peripheral blood eosinophils (PBE) and exhaled nitric oxide (FeNO) accurately predict a sputum eosinophilia?
by: Connolly, CM, et al.
Published: (2017)

Treatment of COVID-19-exacerbated asthma: should systemic corticosteroids be used?
by: Kumar, K, et al.
Published: (2020)

Biological therapies for asthma
by: Couillard Castonguay, S, et al.
Published: (2021)

Fractional exhaled nitric oxide (FeNO) among office workers in an academic institution, Malaysia – associations with asthma, allergies and office environment
by: Lim, Fang Lee, et al.
Published: (2016)

A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE)
by: Couillard, S, et al.
Published: (2021)

Fluticasone furoate: CAPTAIN of fluticasones in type 2 inflammatory asthma
by: Couillard, S, et al.
Published: (2022)

Severe eosinophilic asthma: a roadmap to consensus.
by: Buhl, R, et al.
Published: (2017)

Asthma in pregnancy: An update
by: Couillard, S, et al.
Published: (2020)

Genome-wide association study to identify genetic determinants of severe asthma.
by: Wan, Y, et al.
Published: (2012)